

The Immunological Basis for Immunization Series

Module 15: Meningococcal disease
Updated 2020



World Health
Organization

The Immunological Basis for Immunization Series

**Module 15: Meningococcal disease
Update 2020**



**World Health
Organization**

The immunological basis for immunization series. Module 15: meningococcal disease. Update 2020

(Immunological basis for immunization series ; module 15)

ISBN

ISBN 978-92-4-001748-1 (electronic version)

ISBN 978-92-4-001749-8 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the
Creative Commons Attribution-Non Commercial-ShareAlike 3.0 IGO licence
(CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The immunological basis for immunization series: module 15: meningococcal disease. Update 2020. Geneva: World Health Organization; 2020 (Immunological basis for immunization series; module 15).
Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>.
To submit requests for commercial use and queries on rights and licensing,
see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

<i>Abbreviations and acronyms</i>	<i>vi</i>
<i>Preface</i>	<i>viii</i>
<i>Acknowledgements</i>	<i>ix</i>
<i>Conflict of interest</i>	<i>x</i>
1. Meningococcal disease	1
1.1 Introduction	1
1.2 <i>Neisseria meningitidis</i>	1
1.3 Epidemiology.....	1
1.3.1 Disease caused by <i>N. meningitidis</i> serogroup A.....	2
1.3.2 Disease caused by <i>N. meningitidis</i> serogroup B	4
1.3.3 Disease caused by <i>N. meningitidis</i> serogroup C.....	4
1.3.4 Disease caused by <i>N. meningitidis</i> serogroup W	4
1.3.5 Disease caused by <i>N. meningitidis</i> serogroup X.....	5
1.3.6 Disease caused by <i>N. meningitidis</i> serogroup Y	5
1.4 Risk factors for meningococcal carriage	5
1.5 Risk factors for meningococcal disease	6
1.6 Clinical presentation	6
1.7 Diagnosis.....	6
1.8 Treatment	7
2. Immunity to meningococci	8
3. Immunological assays	11
3.1 Serum bactericidal antibody assay.....	11
3.2 Measurement of serogroup-specific immunoglobulin.....	13
3.3 Opsonophagocytic assays	13
3.4 Other assays.....	14
4. Surrogates of protection	15
5. Available vaccines	18

6.	Response to immunization	25
6.1	<i>Meningococcal polysaccharide vaccines.....</i>	25
6.2	<i>Meningococcal conjugate vaccines.....</i>	27
6.2.1	Monovalent serogroup C conjugate vaccines.....	27
6.2.2	Quadrivalent meningococcal polysaccharide-protein conjugate vaccines	30
6.2.2.1	<i>MCV4-DT.....</i>	30
6.2.2.2	<i>MCV4-CRM.....</i>	31
6.2.2.3	<i>MCV4rix-TT.....</i>	31
6.2.2.4	<i>MCV4fi-TT.....</i>	33
6.2.3	Monovalent serogroup A conjugate vaccines.....	34
6.2.4	Pentavalent ACWYX vaccines.....	35
6.2.5	Combination vaccines.....	36
6.3	<i>Meningococcal protein vaccines</i>	36
6.3.1	Outer membrane vesicle (OMV) vaccines	36
6.3.2	4CMenB	38
6.3.3	Bivalent rLP2086.....	41
6.4	<i>Clinical risk groups</i>	42
6.4.1	Asplenia.....	42
6.4.2	Pre-term infants.....	42
6.4.3	Human immunodeficiency virus (HIV).....	43
6.4.4	Complement deficiency.....	43
6.4.5	Standard and intensive chemotherapy.....	44
6.4.6	Malaria, malaria chemoprophylaxis and sickle-cell trait.....	44
7.	Effectiveness	45
7.1	<i>Polysaccharide vaccines</i>	45
7.1.1	Serogroup C.....	45
7.1.2	Serogroup A.....	46
7.1.3	Serogroups Y and W	47
7.2	<i>Conjugate vaccines</i>	47
7.2.1	Serogroup C (MCC)	47
7.2.2	Serogroup A	48
7.2.3	Quadrivalent ACWY.....	49
7.3	<i>Protein vaccines.....</i>	49
7.3.1	Outer membrane vesicle (OMV) vaccines	49
7.3.2	4CMenB vaccine.....	50
8.	Safety	51
8.1	<i>Polysaccharide vaccines</i>	51
8.2	<i>Conjugate vaccines</i>	52
8.2.1	Meningococcal C conjugate vaccines	52
8.2.2	Meningococcal A conjugate vaccines	53
8.2.3	Meningococcal quadrivalent ACWY conjugate vaccines.....	54
8.3	<i>Meningococcal B vaccines.....</i>	55
8.4	<i>Combination vaccines.....</i>	56

9. Concomitant use.....	57
9.1 <i>Coadministration in infants, toddlers and young children.....</i>	<i>58</i>
9.2 <i>Coadministration in adolescents.....</i>	<i>59</i>
9.3 <i>Coadministration in Adults.....</i>	<i>61</i>
10. Effect of vaccines against carriage	62
10.1 <i>Polysaccharide vaccines</i>	<i>62</i>
10.2 <i>Conjugate vaccines</i>	<i>62</i>
10.3 <i>Protein vaccines.....</i>	<i>63</i>
10.4 <i>Mechanism of action</i>	<i>64</i>
11. Implications for immunization	65
12. References	66

Abbreviations and acronyms

4CMenB	Bexsero
ACIP	Advisory Committee on Immunization Practices (US)
aHUS	atypical haemolytic uraemic syndrome
ALL	acute lymphoblastic leukaemia
AML	acute myeloid leukaemia
aP	acellular pertussis
CDC	Centers for Disease Control and Prevention (US)
CEACAM	human carcinoembryonic antigen-related cell adhesion molecule
CI	confidence interval
CRM197	non toxigenic natural variant of diphtheria toxin
DT	diphtheria-tetanus
DTaP	diphtheria-tetanus-acellular pertussis
DTwP	diphtheria-tetanus-whole cell pertussis
ECDC	European Centre for Disease Prevention and Control.
ELISA	enzyme-linked immunosorbent assay
EPI	Expanded Programme on Immunization
FDA	Food and Drug Administration (USA)
GBS	Guillain-Barré syndrome
GMT	geometric mean titre
GSK	GlaxoSmithKline Biologicals
Hib	<i>Haemophilus influenzae</i> type b
HBV	hepatitis B virus
HPV	human papillomavirus
hSBA	serum bactericidal antibody measured with exogenous human complement
HSCT	hematopoietic stem cell transplant
Ig	immunoglobulin
IOM	Institute of Medicine (US)
IPV	inactivated polio vaccine
JE	Japanese encephalitis

LCCD	late complement component deficiency
LOS	lipooligosaccharide
LP	lipoprotein
MATS	Meningococcal Antigen Typing System
MCC	meningococcal serogroup C conjugate
MCV4	meningococcal quadrivalent ACWY conjugate vaccine
MCV4-CRM	Menveo
MCV4-DT	Menactra
MCV4fi-TT	MenQuadfi
MCV4rix-TT	Nimenrix
ME	myalgic encephalomyelitis
MHRA	Medicines and Healthcare Products Regulatory Agency
MLST	multilocus sequence type
MMR	measles, mumps and rubella vaccine
MVP	Meningitis Vaccine Project
NACI	National Advisory Committee on Immunization Canada
NHBA	Neisseria Heparin Binding Antigen
OPA	opsonophagocytosis
OMP	outer membrane protein
OMV	outer membrane vesicle
PCR	polymerase chain reaction
PCV7	pneumococcal 7-valent conjugate vaccine
PNH	paroxysmal nocturnal haemoglobinuria
PsA-TT	MenAfriVac
rLP2086	Trumenba
rSBA	serum bactericidal antibody measured with exogenous rabbit complement
SAE	serious adverse event

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24686

